Abbott (ABT -0.4%) says its humanised monoclonal antibody for the treatment of glioma has been...

|About: Abbott Laboratories (ABT)|By:, SA News Editor

Abbott (ABT -0.4%) says its humanised monoclonal antibody for the treatment of glioma has been granted orphan designation by the European Commission. Glioma affects approximately 1 in 10K people in the European Union, or the equivalent of a total of around 51K people.